Moderna (NASDAQ:MRNA) Upgraded to “C” by TheStreet

TheStreet upgraded shares of Moderna (NASDAQ:MRNA) from a d+ rating to a c rating in a research note published on Tuesday, TheStreetRatingsTable reports.

Other analysts have also issued research reports about the company. Piper Sandler lifted their price objective on Moderna from $100.00 to $134.00 in a report on Wednesday, July 15th. Chardan Capital reiterated a buy rating and set a $95.00 price target on shares of Moderna in a research note on Wednesday, August 12th. JPMorgan Chase & Co. restated a hold rating on shares of Moderna in a research note on Thursday, August 6th. Zacks Investment Research upgraded shares of Moderna from a hold rating to a buy rating and set a $86.00 target price on the stock in a research report on Tuesday, July 21st. Finally, Goldman Sachs Group set a $105.00 price target on shares of Moderna and gave the stock a buy rating in a research report on Monday, July 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $87.44.

MRNA opened at $59.34 on Tuesday. The firm has a market cap of $23.41 billion, a P/E ratio of -42.39 and a beta of 0.47. The business has a 50 day moving average price of $69.60 and a 200 day moving average price of $54.58. Moderna has a twelve month low of $13.53 and a twelve month high of $95.21.

Moderna (NASDAQ:MRNA) last released its earnings results on Wednesday, August 5th. The company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.05. The firm had revenue of $66.35 million during the quarter, compared to analyst estimates of $24.24 million. Moderna had a negative net margin of 461.42% and a negative return on equity of 27.85%. The company’s quarterly revenue was up 407.2% on a year-over-year basis. On average, research analysts expect that Moderna will post -1.54 EPS for the current year.

In related news, Director Elizabeth G. Nabel sold 73,975 shares of the business’s stock in a transaction that occurred on Wednesday, July 15th. The stock was sold at an average price of $87.84, for a total transaction of $6,497,964.00. Following the transaction, the director now directly owns 54,651 shares of the company’s stock, valued at approximately $4,800,543.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Stephane Bancel sold 4,521 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $65.92, for a total value of $298,024.32. Following the completion of the sale, the chief executive officer now owns 6,734,858 shares in the company, valued at approximately $443,961,839.36. The disclosure for this sale can be found here. Insiders sold 868,820 shares of company stock valued at $59,850,433 over the last three months. 29.20% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in MRNA. Bessemer Group Inc. acquired a new stake in Moderna during the second quarter worth approximately $27,000. Corbenic Partners LLC acquired a new position in Moderna in the 2nd quarter valued at $32,000. BDO Wealth Advisors LLC bought a new position in Moderna during the 2nd quarter worth $32,000. Global Wealth Management Investment Advisory Inc. boosted its position in shares of Moderna by 124.0% in the second quarter. Global Wealth Management Investment Advisory Inc. now owns 560 shares of the company’s stock valued at $36,000 after acquiring an additional 310 shares during the period. Finally, Pacitti Group Inc. grew its stake in shares of Moderna by 175.6% in the second quarter. Pacitti Group Inc. now owns 620 shares of the company’s stock valued at $44,000 after acquiring an additional 395 shares in the last quarter. 55.04% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit